mentofGlaucomaSAFLUTANModule3v6
- 1. 1 Preservative-Free Solutions in the Treatment of Glaucoma Profile of SAFLUTAN™† (tafluprost) †SAFLUTAN is a trademark of Merck & Co., Inc., Whitehouse Station, NJ, USA.
- 2. 2 Introduction Preservative-free formulations of glaucoma medications may have a positive impact on ocular health Minimizing damage to the ocular surface by using a preservative-free formulation may improve patient comfort and increase compliance Tolerability issues may affect quality of life and lead to nonadherence Comprehensive management of glaucoma needs to include IOP- lowering efficacy as well as long-term safety SAFLUTAN™† (tafluprost) is the first preservative-free prostaglandin that reduces IOP effectively and is associated with a high degree of patient comfort, which may promote compliance IOP = intraocular pressure †SAFLUTAN is a trademark of Merck & Co., Inc., Whitehouse Station, NJ, USA.
- 3. 3 Learning Objectives Understand the differences between preserved and preservative-free solutions, their impact on ocular health, and implications for the management of glaucoma Review the efficacy profile of SAFLUTAN™† (tafluprost) to understand its IOP-lowering effects, the extent to which these effects are maintained over time, and how SAFLUTAN’s efficacy compares to that of latanoprost Review the safety/tolerability profile of SAFLUTAN to understand its effects on ocular health and symptoms and signs relative to latanoprost IOP = intraocular pressure †SAFLUTAN is a trademark of Merck & Co., Inc., Whitehouse Station, NJ, USA.
- 4. 4 BAK Concentrations of Select Prostaglandin Analogues 0 0.01 0.02 0.03 Latanoprost (Xalatan®) Travoprost (Travatan®) Tafluprost (SAFLUTAN™†) Bimatoprost (Lumigan®) BAKConcentration(%) BAK = benzalkonium chloride Xalatan Prescribing Information. Pfizer Manufacturing, Puurs, Belgium.: 2009; Travatan Prescribing Information. http://rxlist.com/travatan-drug.htm. Accessed March 11, 2009; Lumigan Prescribing Information. Allergan, Inc., Irvine, CA.: 2006; SAFLUTAN Summary of Product Characteristics. Merck & Co., Inc., Whitehouse Station, NJ, USA.: 2008. †SAFLUTAN is a trademark of Merck & Co., Inc., Whitehouse Station, NJ, USA.
- 5. 5 Preservative-Free Eye Drops: Reduced Symptomsa ap < 0.0001 for all comparisons between groups. Jaenen N et al. Eur J Ophthalmol. 2007;17(3):341–349. 0 10 20 30 40 50 Pain or discomfort Foreign body sensation Stinging or burning Dry eye sensation Preserved Preservative-free Patients(%) N = 9,658
- 6. 6 Preservative-Free Eye Drops: Reduced Signsa ap < 0.0001 for all comparisons between groups. Jaenen N et al. Eur J Ophthalmol. 2007;17(3):341–349. 0 10 20 30 40 50 60 Hyperaemia Blepharitis (anterior/posterior) Superficial punctate keratitis Fluorescein staining Preserved Preservative-free Patients(%) N = 9,658
- 7. 7 Comprehensive Glaucoma Management Ocular tolerability Long-term safety Long-term control IOP = intraocular pressure Patient remaining on therapy IOP-lowering efficacy
- 8. 8 Profile of SAFLUTAN™† (tafluprost) SAFLUTAN™† (tafluprost) is a new prostaglandin analogue for the treatment of glaucoma and is indicated for: – Reduction of elevated IOP in open angle glaucoma and ocular hypertension • As monotherapy in patients: – Who would benefit from preservative-free eye drops – Who are insufficiently responsive to first line therapy – Who are intolerant or contraindicated to first line therapy • As adjunctive therapy to beta-blockers SAFLUTAN is the first preservative-free prostaglandin SAFLUTAN is a highly potent and selective FP-receptor agonist SAFLUTAN reduces IOP effectively in animal models, healthy volunteers, and glaucoma patients SAFLUTAN is associated with fewer adverse signs and symptoms than latanoprost, the leading prostaglandin SAFLUTAN is associated with a high degree of patient comfort, which may promote compliance FP = prostaglandin F; IOP = intraocular pressure SAFLUTAN Summary of Product Characteristics. Merck & Co., Inc., Whitehouse Station, NJ, USA.: 2008; Ophthalmol Times Eur. 2008;4(5):1; Takagi Y et al. Exp Eye Res. 2004;78:767–776; Pisella PJ et al. Br J Ophthalmol. 2002;86:418–423; Ropo A et al. 4th International Congress on Glaucoma Surgery; April 16–18, 2009, Geneva, Switzerland. Poster. †SAFLUTAN is a trademark of Merck & Co., Inc., Whitehouse Station, NJ, USA.
- 9. 9 SAFLUTAN™† (tafluprost) Has High FP Receptor Affinity: 12 Times Greater Than Latanoprost Prostaglandin Receptor-Binding Affinity (Moles per Liter)a Prostaglandin Analogueb FP EP1 EP2 EP3 IP/DP TP PGF2α 1.2× 10−8 3.2× 10−7 6.4× 10−6 1.6× 10−7 >10−4 > 10−4 Latanoprost acid 1.0× 10−8 5.0× 10−6 >10−4 2.8× 10−5 >10−4 > 10−4 Travoprost 3.5× 10−9 3.0× 10−8 >10−4 2.4× 10−5 >10−4 > 10−4 Bimatoprost 4.5× 10−9 6.5× 10−7 >10−4 >10−4 >10−4 3.4× 10−5 Tafluprost 0.5× 10−9 >10−6 >10−6 6.7× 10−8 >10−6 > 10−6 EC50 = half maximal effective concentration; FP = prostaglandin F; PGF2α = prostaglandin F2α aReceptor binding assessed according to EC50 values. bData refer to active drug product. Stjernschantz JW. From PGF2α-isopropyl ester to latanoprost: a review of the development of Xalantan. Inv Ophthalmol Vis Sci. 2001;42(6):1134–1145; Stjernschantz JW et al. Mechanism and clinical significance of prostaglandininduced iris pigmentation. Surv Ophthalmol. 2002;47(suppl 1):S162–S175; Takagi Y et al. Exp Eye Res. 2004;78:767–776. †SAFLUTAN is a trademark of Merck & Co., Inc., Whitehouse Station, NJ, USA. Higher FP affinity has not been correlated with an increase in either efficacy or safety
- 10. 10 Preservative-free and preserved tafluprost similarly penetrate the aqueous humor BAK is not necessary for tafluprost to penetrate the cornea Preserved vs Preservative-Free Tafluprost: Equivalent Penetration N=48, as 6 groups of 8 Preservative-free tafluprost 0.0015% in one eye and preserved tafluprost 0.0015% in the other eye Tafluprost acid concentration in aqueous humor assessed at 6 time points: 45 minutes and 1.5, 2, 3, 6, and 8 hours Pharmacokinetic Parameter Preservative-Free Tafluprost Preserved Tafluprost Cmax (ng/mL) 4.50 3.99 AUC3h (ng•h/mL) 5.14 4.54 AUC = area under curve; BAK = benzalkonium chloride; Cmax = maximum concentration Reprinted with permission from Pellinen P et al. Ophthalmic Res. 2009;41:118–122.
- 11. 11 Tafluprost Is Safe and Effective in Healthy Human Volunteers Study 1 Phase I study of 16 healthy volunteers Tafluprost at 0.0001%, 0.0005%, 0.0025%, and 0.005% versus placebo Sequentially ascending doses Decrease in IOP was greater with 0.0025% and 0.005% tafluprost than with 0.0001% tafluprost Tafluprost was generally well tolerated Study 2 Phase I study of 49 healthy volunteers Tafluprost at 0.0025% or 0.005%, latanoprost at 0.005%, or placebo Once daily for 7 days IOP reduction was greater with 0.005% tafluprost than with 0.005% latanoprost or placebo Tafluprost was generally well tolerated IOP = intraocular pressure Sutton A et al. Int J Clin Pharmacol Ther. 2008;46:400–406.
- 12. 12 Tafluprost and Latanoprost Reduce IOP in Healthy Volunteers (Study 2) IOP = intraocular pressure ap < 0.05, bp < 0.01, cp < 0.001 for tafluprost (0.005%) versus placebo. dp < 0.05, ep < 0.01 for tafluprost (0.005%) versus latanoprost. fp < 0.005 for latanoprost versus placebo. Adapted with permission from Sutton A et al. J Ocul Pharmacol Ther. 2007;23:359–365. -8 -7 -6 -5 -4 -3 -2 -1 0 +1 +2 +4 +8 +12 +24 +12 +12 +12 +12 +12 +24 +1 +2 +4 +8 +12 +24 MeanChangeFromBaselineIOP(mmHg) Tafluprost (0.0025%) Tafluprost (0.005%) Placebo Latanoprost (0.005%) Day 1 D2 D3 D4 D5 D6 Day 7 a,d c b,d b b,d b a a c a a f f
- 13. 13 Preservative Has No Influence on the Efficacy of Tafluprost in an Open-Label Trial 14 16 18 20 22 24 26 IOP(mmHg) p = 0.96 Week 1 8:00 12:00 16:00 20:00 Baseline 8:00 12:00 16:00 20:00 Week 4 8:00 12:00 16:00 20:00 Visit and Time Preserved tafluprost (N = 42) Preservative-free tafluprost (N = 43) IOP = intraocular pressure Adapted with permission from Hamacher T et al. Acta Ophthalmol. 2008;86(Suppl 242):14–19; Data on file, MSD ____.
- 14. 14 Similar Efficacy and Safety of Tafluprost and Latanoprost in Glaucoma Patients Methods – 38 patients with open-angle glaucoma or ocular hypertension – 6-week treatment with tafluprost (0.0015%) or latanoprost (0.005%) Results – Mean IOP reduction was similar • 33% for both groups – IOP reduction was stable for 24 hours – Adverse events were few and evenly distributed between groups – Conjunctival hyperaemia: low incidence and mostly mild Conclusion – IOP-lowering efficacy and safety profile of tafluprost are comparable to those of latanoprost IOP = intraocular pressure Papadia M et al. Association for Research in Vision and Ophthalmology; April 30–May 4, 2006, Ft. Lauderdale, FL. Poster.
- 15. 15 14 16 18 20 22 24 26 28 IOP(mmHg) Efficacy of Tafluprost vs Latanoprost p = 0.81 Data on file, MSD ____. Day 7 8:00 Day 0 8:00 12:00 16:00 20:00 Day 42 8:00 12:00 16:00 20:00 Day 21 8:00 N = 36 Visit and Time 33% Mean Reduction From Baseline Tafluprost Latanoprost
- 16. 16 Long-Term Study of Tafluprost: Efficacy and Safety Long-term phase III study of tafluprost vs latanoprost – Methods • Patients with open-angle glaucoma or ocular hypertension • 49 centers in 8 countries • 6-month study extended to 24 months – Primary outcome measure assessed at 6 months • Tafluprost (0.0015%) or latanoprost (0.005%), once daily – 533 patients randomized (n = 269 tafluprost; n=264 latanoprost) – 420 patients continued into extension interval (n = 196 tafluprost; n = 224 latanoprost) – After washout, patients were required to have an IOP of 22–34 mmHg in at least one eye at baseline • Key endpoint: – Change in IOP from washout baseline IOP = intraocular pressure Data on file, MSD ____.
- 17. 17 Sustained IOP Reduction Comparable to Latanoprost Over 24 Months From a Washout Baseline Double-masked, active-controlled, parallel-group, multinational, multicenter, 24-month phase III study of tafluprost preserved form vs latanoprost 0.0 2.0 4.0 6.0 8.0 10.0 12.0 14.0 16.0 18.0 20.0 22.0 24.0 26.0 28.0 30.0 mmHg,Mean Sustained IOP Control Over 24 Monthsa Baseline Month 6 Month 12 Month 18 Month 24 Hours 8 12 16 20 Tafluprost (N = 185 at 24 months) Latanoprost (N = 217 at 24 months) b b c c 8 12 16 208 12 16 208 12 16 208 12 16 20 CI = confidence interval; IOP = intraocular pressure; NS = not significant; RM ANOVA = repeated measurements of analysis of variance aData based on 511 patients who had IOP measurements at 3 months or later. bUpper 95% CI (RM ANOVA) was 1.54 and 1.70 at 6 and 12 months, respectively (p = NS compared to latanoprost). cUpper 95 CI (RM ANOVA) was 1.33 and 1.44 at 18 and 24 months, respectively. Data on file, MSD ____.
- 18. 18 IOP Control Maintained Following Switch from Latanoprost to SAFLUTAN™† (tafluprost)a in an Open-Label Trial Switching from preserved latanoprost to preservative-free SAFLUTAN had no impact on IOP reduction IOP reduction maintained over the entire 12-week trial IOP = intraocular pressure aIn a 12-week, multinational, phase IIIb, open-label study evaluating changes in ocular signs and symptoms in patients switched from latanoprost to preservative-free SAFLUTAN. bPatients were diagnosed with open-angle glaucoma or ocular hypertension; used latanoprost ≥6 months and had ≥2 symptoms, or 1 sign and 1 symptom. Ropo A et al. 4th International Congress on Glaucoma Surgery, Geneva, Switzerland, April 16–18, 2009. †SAFLUTAN is a trademark of Merck & Co., Inc., Whitehouse Station, NJ, USA. 30 29 28 27 26 20 19 18 17 16 15 14 13 12 10 0 2 weeks 6 weeks 12 weeks Tafluprost (N = 158) Latanoprost (N = 158) MeanIOP(mmHG) p < 0.001 p = 0.003 p = 0.33
- 19. 19 Tafluprost Is Suitable for Adjunctive Therapy Phase III study of 185 patients – Primary open-angle glaucoma or ocular hypertension not controlled by timolol monotherapy Tafluprost (0.0015%) or vehicle, once daily – As adjunct to 0.5% timolol twice daily for 6 weeks Primary end point: – Change from baseline in diurnal IOP at 6 weeks Tafluprost was superior to vehicle – IOP reduction of ≥30% from baseline: 27% vs 14% for vehicle – More ocular adverse events with tafluprost than with vehicle (42% vs 29%), but most were mild IOP = intraocular pressure Egorov E et al. Eur J Ophthalmol. 2009;19:214–222.
- 20. 20 In Vitro Effect of SAFLUTAN™† (tafluprost) on Conjunctival Cells Was Most Similar to Salinea Immortalized human conjunctival cells were used in this analysis of preservative-free tafluprost’s effect on cell membrane integrity Membrane integrity following treatment was 53% with BAK 0.005%, 43% with BAK 0.015%, and 37% with BAK 0.02% vs control (p < 0.001 between treatments) It was noted that results obtained in an in vitro model could not be fully extrapolated to in vivo conditions The clinical relevance of these findings is unknown BAK = benzalkonium chloride; PBS = phosphate-buffered saline aIn vitro membrane integrity of human conjunctival epithelial cells after 30-minute exposure to PBS control, BAK 0.005%, BAK 0.015%, BAK 0.02%, and preservative-free tafluprost. bp < 0.05 vs control. cp < 0.001 tafluprost vs latanoprost. Adapted with permission from Brasnu E et al. Curr Eye Res. 2008;33:303–312. †SAFLUTAN is a trademark of Merck & Co., Inc., Whitehouse Station, NJ, USA. 0 20 40 60 80 100 CellMembraneIntegrity,% Control (PBS) Tafluprost 91%b 100% 37% Latanoprost
- 21. 21 Use of Tafluprost With Timolol Provides Additive Effects for Reduction of IOP IOP = intraocular pressure aMean (± standard error of the mean; SEM) diurnal IOP with tafluprost or vehicle, as adjunctive to timolol. bVehicle in this study comprised the same formulation as SAFLUTAN, without the tafluprost ingredient. Adapted with permission from Egorov E et al. Eur J Ophthalmol. 2009;19(2):214–222. †SAFLUTAN is a trademark of Merck & Co., Inc., Whitehouse Station, NJ, USA. Randomized, double-masked, parallel-group, multinational, multicenter phase III open-label studya 10.0 11.0 12.0 13.0 14.0 15.0 16.0 17.0 18.0 19.0 20.0 21.0 22.0 23.0 24.0 25.0 26.0 27.0 28.0 29.0 30.0 DiurnalIOP(mmHg),Mean±SEM Timolol + SAFLUTAN™† (tafluprost) (N = 96) Timolol + vehicle (N = 89)b Patients switched to concomitant SAFLUTAN from concomitant vehicle 8 10 16 8 10 16 8 10 16 8 10 16 8 10 168 Baseline Screening (4-week timolol run-in) Week 2 Week 4 Week 6 Week 8 Week 12 At Week 6, all patients received tafluprost Double-Masked Open-Label Hours p < 0.001 at 6 weeks (primary end point)
- 22. 22 0 10 20 30 40 50 60 70 80 Latanoprost (Baseline; N = 158) SAFLUTAN (Week 12; N = 158) Irritation/ burning/ stinging Itching Foreign body sensation Tearing PatientsWithAbnormalValues,% Fewer Ocular Symptoms with SAFLUTAN™† (tafluprost) Compared to Latanoprosta SAFLUTAN provided dramatic reduction in ocular symptoms across each category vs latanoprost Improvements seen at Week 12 Ocular Symptomsb,c (p < 0.001) Dry eye sensation aIn a 12-week, multinational, phase IIIb, open-label study evaluating changes in ocular signs and symptoms in patients switched from latanoprost to preservative-free SAFLUTAN. bPatients were diagnosed with open-angle glaucoma or ocular hypertension; used latanoprost ≥6 months and had ≥2 symptoms, or 1 sign and 1 symptom. cSymptoms reported as mild in severity were considered abnormal. Ropo A et al. 4th International Congress on Glaucoma Surgery, Geneva, Switzerland, April 16–18, 2009. †SAFLUTAN is a trademark of Merck & Co., Inc., Whitehouse Station, NJ, USA.
- 23. 23 SAFLUTAN provided dramatic reduction in ocular signs across each category vs latanoprost Improvements seen at Week 12 Fewer Ocular Signs for SAFLUTAN™† (tafluprost) Compared to Latanoprosta,b aIn a 12-week, multinational, phase IIIb, open-label study evaluating changes in ocular signs and symptoms in patients switched from latanoprost to preservative-free SAFLUTAN. bPatients were diagnosed with open-angle glaucoma or ocular hypertension; used latanoprost ≥6 months and had ≥2 symptoms, or 1 sign and 1 symptom. cBaseline vs 12 weeks; p < 0.001. dBaseline vs 12 weeks; p < 0.003. Ropo A et al. 4th International Congress on Glaucoma Surgery, Geneva, Switzerland, April 16–18, 2009. †SAFLUTAN is a trademark of Merck & Co., Inc., Whitehouse Station, NJ, USA. 0 10 20 30 40 50 60 70 80 90 100 Baseline (latanoprost) After 12 weeks of treatment with preservative-free tafluprost Tear-film break-up time Corneal fluorescein staining Conjunctival fluorescein staining Conjunctival hyperaemia Patients(%) Blepharitis Tear production c c c c c d
- 24. 24 Preservative-Free Tafluprost Causes Less Cellular Distress Than Latanoprost In vitro study designed to quantify the degree to which prostaglandin analogue formulations induce oxidative stress and apoptosis in human conjunctival cells 0.0 0.5 1.0 1.5 2.0 2.5 3.0 3.5 4.0 4.5 Oxidative Stress Apoptotic Effects DistressRatio (RelativetoControl) c Control (PBS) Tafluprost Latanoprost (0.02% BAK) 0.02% BAK d e d e BAK = benzalkonium chloride; PBS = phosphate-buffered saline aOxidative stress was measured via a probe for hydroethidine, a marker of the superoxide anion. bApoptotic effects were measured via a Yopro-1 probe, which allows for quantification of P2X7 cell death receptor activation. cp < 0.05 compared with control with the Yopro test. dp < 0.001 vs control with hydroethidine test. ep <0.001 vs control with Yopro-1. Adapted with permission from Brasnu E et al. Curr Eye Res. 2008;33(4):303–312. a b
- 25. 25 Summary Management of glaucoma is multifactorial Tolerability problems and administration difficulties associated with glaucoma medications may affect QOL and lead to eye drop discontinuation and poor medical outcomes SAFLUTAN™† (tafluprost) is the first preservative-free prostaglandin analogue and has a high affinity for FP receptors, which have been demonstrated to be strong mediators of the IOP-lowering mechanism SAFLUTAN provides substantial, sustained IOP-lowering efficacy FP = prostaglandin F; IOP = intraocular pressure; QOL = quality of life Chawla A et al. Ophthalmol Scand. 2007;85(4):464; Schwartz GF. Curr Opin Ophthalmol. 2005;16(2)114–121; Pisella PJ et al. Ophthalmic Res. 2000;32:3–8; Jaenen N, et al. Eur J Ophthalmol. 2007;17(3):341–349; First preservative-free prostaglandin treatment approved. Ophthalmol Times Eur. 2008;4(5):1; Takagi Y et al. Exp Eye Res. 2004;78:767–776; Papadia M et al. Association for Research in Vision and Ophthalmology; April 30– May 4, 2006, Ft. Lauderdale, FL. Poster; Data on file, MSD ____. †SAFLUTAN is a trademark of Merck & Co., Inc., Whitehouse Station, NJ, USA.
- 26. 26 Summary (cont) SAFLUTAN™† (tafluprost) does not compromise cell membrane integrity SAFLUTAN is associated with significantly fewer adverse reactions than preserved latanoprost SAFLUTAN is safe and well tolerated Patient satisfaction is greater with SAFLUTAN compared to latanoprost SAFLUTAN provides a risk-benefit ratio that makes it a valuable option for glaucoma patients Brasnu E et al. Curr Eye Res. 2008;33:303–312; Ropo A et al. 4th International Congress on Glaucoma Surgery; April 16–18, 2009, Geneva, Switzerland. Poster; Data on file, MSD ____; Sutton A et al. J Ocul Pharmacol Ther. 2007;23:359–365. †SAFLUTAN is a trademark of Merck & Co., Inc., Whitehouse Station, NJ, USA.
- 27. 27 Preservative-Free Solutions in the Treatment of Glaucoma †SAFLUTAN is a trademark of Merck & Co., Inc., Whitehouse Station, NJ, USA. Before prescribing SAFLUTAN™† (tafluprost), please read the full Prescribing Information. Merck does not recommend the use of any product in any different manner than as described in the Prescribing Information. Adapted with permission from Elsevier. Copyright © 2009. Distributed with permission from Santen Pharmaceutical Co., Ltd. Copyright © 2009 Merck & Co., Inc. All rights reserved. 07-10 RTG-2009-W-1289116-SS Visit us on the World Wide Web at www.merck.com
- 28. 28 BACK UP
- 29. 29 Preservative-Free Tafluprost: In Vivo Data 24 rabbits total: 6 per group – Preservative-free tafluprost – Latanoprost (0.02% BAK) – PBS (0.02% BAK) – PBS (control) Results assessed at 4 hours and Day 1 – Day 7, via: – In vivo confocal microscopy – Slit-lamp biomicroscopy – Conjunctival impression cytology – Flow cytometry – Immunohistology • CD45: marker of inflammation • TUNEL: marker of apoptosis 1 drop every 5 minutes; 15 times total BAK = benzalkonium chloride; PBS = phosphate-buffered saline; TUNEL = terminal deoxynucleotidyl transferase mediated dUTP (uridine 5′ triphosphate) nick end labeling Liang H et al. Br J Ophthalmol. 2008;92:1275–1282.
- 30. 30 Preservative-Free Tafluprost: In Vivo Data Evaluation of ocular surface abnormalities by in vivo confocal microscopy BAK = benzalkonium chloride; PBS = phosphate-buffered saline ap < 0.0005 versus control (PBS). bp < 0.0005 versus preservative-free tafluprost. cp < 0.005 versus latanoprost. Adapted with permission from Liang H et al. Br J Ophthalmol. 2008;92:1275–1282. 0 2 4 6 8 10 12 14 16 18 20 Control (PBS) Preservative-free tafluprost Xalatan (latanoprost; 0.02% BAK) PBS with 0.02% BAK 4 Hours 1 Day a, b a, b, c SurfaceAbnormalityScore
- 31. 31 IOP = intraocular pressure Sutton A et al. Int J Clin Pharmacol Ther. 2008;46:400–406. Tafluprost Reduced IOP in Healthy Volunteers -5 -4 -3 -2 -1 0 0.0001% 0.0005% 0.0025% 0.005% MaximalIOPComparedWithPlacebo(mmHg) Tafluprost Concentration Maximal Effects Seen After 12 Hours on Day 2 of Testing
- 32. 32 Greater Patient Satisfaction With SAFLUTAN™† (tafluprost) Compared to Latanoprost Greater patient satisfaction was seen in patients switching to preservative-free SAFLUTAN than in patients receiving preserved latanoprost Patients were diagnosed with open-angle glaucoma or ocular hypertension, used latanoprost ≥6 months, and had ≥2 symptoms or 1 sign and 1 symptom Ropo A et al. 4th International Congress on Glaucoma Surgery, Geneva, Switzerland, April 16–18, 2009. †SAFLUTAN is a trademark of Merck & Co., Inc., Whitehouse Station, NJ, USA. 0 10 20 30 40 50 Baseline (latanoprost) After 12 weeks of treatment with preservative-free tafluprost Totally satisfied Very satisfied Baseline vs 12 weeks p < 0.001 N = 158 Patients(%)
- 33. 33 Conjunctival Hyperaemia With Prostaglandins 0 10 20 30 40 50 Xalatan (latanoprost) Travatan (travoprost) Lumigan (bimatoprost) Patients(%) Xalatan Summary of Product Characteristics. Pfizer Manufacturing, Sandwich, Kent, UK.: 2007; Travatan Summary of Product Characteristics. Alcon Laboratories, Hemel Hempstead, Hertfordshire, UK.: 2006; Lumigan Summary of Product Characteristics. Allergan Ltd, Marlow, Bucks, UK.: 2007. All available at: http://emc.medicines.org.UK/browsedocuments.aspx. Accessed May 30, 2009.